PeptiDream : awarded Leadership level in CDP’s 2022 Climate Change Report (87KB）

News Release

January 10, 2023

PeptiDream Inc https://www.peptidream.com(Securities Code: 4587 TSE Prime Market)

PeptiDream awarded Leadership level in

CDP's 2022 Climate Change Report

KANAGAWA, JAPAN - January 10, 2023 - PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587) today announced that PeptiDream has been recognized by CDP* for its leadership in climate change with an A- (A minus) rating. PeptiDream reached the Leadership level, the highest level, as a company that excels in its efforts and information disclosure in climate change.

The CDP assessment analyzes the quality of companies' initiatives and information disclosure in the areas of Climate Change, Forests, and Water Security, and ranks companies on a scale of "A" to "D-." PeptiDream was awarded Leadership level (A, A-) for its progressive efforts to address climate change. In 2022, a record number of approx. 18,700 companies responded to this survey.

PeptiDream has identified climate change as one of its priority issues (materiality). In January 2022, PeptiDream achieved "carbon neutral" across its business operations by switching 100% of the electricity consumed in its business activities to renewable energy sources that emit virtually no CO2.

PeptiDream will continue to increase the efficiency of its business operations for the sustainable growth of the society. The company will promote business operations that are friendly to the global environment, while continuing to engage in dialogues with various stakeholders.

*CDP (Carbon Disclosure Project):

An international non-profit organization that promotes environmental issues such as climate change, water resource conservation and forest conservation. CDP requests companies to disclose information based on demands from institutional investors worldwide who have a high interest in environmental issues.

About PeptiDream Inc.

PeptiDream Inc. (Tokyo Stock Exchange Prime Section 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. Founded in 2006, PeptiDream employs its proprietary Peptide Discovery Platform System (PDPS) technology,

1. state-of-the-arthighly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, or peptide-drug conjugate (PDC)-based therapeutics

and diagnostics. PeptiDream has an extensive global network of discovery and development partners driving the development and commercialization of a broad and diversified pipeline of

investigational therapeutics. PeptiDream also markets and sells a number of radiopharmaceutical and radiodiagnostic products in Japan, through its wholly owned subsidiary, PDRadiopharma. PeptiDream is headquartered in Kawasaki, Japan. For more information about our company, science and pipeline, please visit www.peptidream.com

Inquiries:

PeptiDream Inc.

Contact: Yuko Okimoto, IR & Public Affairs

Email: [e-mail]